CGEM
Cullinan Oncology LLC
NASDAQ: CGEM · HEALTHCARE · BIOTECHNOLOGY
$15.56
+4.85% today
Updated 2026-10-28
Market cap
$859.18M
P/E ratio
—
P/S ratio
25.86x
EPS (TTM)
$-3.11
Dividend yield
—
52W range
$7 – $23
Volume
1.0M
Cullinan Oncology LLC (CGEM) Insider transactions
Net insider activity
Net buying (5,467,637 shares)
Buy transactions
54
Sell transactions
46
All transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-08 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 4,000 | — | — |
| 2026-09-08 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 8,000 | $21.57 | $172560.00 |
| 2026-09-08 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 4,000 | $4.30 | $17200.00 |
| 2026-08-13 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 30,000 | — | — |
| 2026-08-13 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 30,000 | $4.30 | $129000.00 |
| 2026-07-06 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 4,000 | — | — |
| 2026-07-06 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 8,000 | $17.82 | $142560.00 |
| 2026-07-06 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 4,000 | $4.30 | $17200.00 |
| 2026-06-30 | SUMER, JACQUELYN L | Chief Legal Officer | Buy | 2,470 | $8.60 | $21242.00 |
| 2026-06-30 | FENTON, MARY KAY | Chief Financial Officer | Buy | 1,541 | $8.60 | $13252.60 |
| 2026-06-16 | WEBSTER, STEPHEN W | Director | Buy | 25,319 | — | — |
| 2026-06-16 | THISTLE, MARY | Director | Buy | 25,319 | — | — |
| 2026-06-16 | ROSENBERG, ANTHONY | Director | Buy | 25,319 | — | — |
| 2026-06-16 | MEEK, DAVID D. | Director | Buy | 25,319 | — | — |
| 2026-06-16 | DOYLE, MITTIE | Director | Buy | 21,781 | — | — |
| 2026-06-16 | ALLEN, ANDREW R | Director | Buy | 21,781 | — | — |
| 2026-05-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 4,000 | — | — |
| 2026-05-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 7,800 | $14.60 | $113880.00 |
| 2026-05-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 4,000 | $4.30 | $17200.00 |
| 2026-05-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 200 | $15.58 | $3116.00 |
| 2026-03-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 4,000 | — | — |
| 2026-03-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 8,000 | $15.68 | $125440.00 |
| 2026-03-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 4,000 | $4.30 | $17200.00 |
| 2026-02-25 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 1,780 | $14.14 | $25169.20 |
| 2026-02-24 | SUMER, JACQUELYN L | Chief Legal Officer | Sale | 3,601 | $14.47 | $52106.47 |
| 2026-02-24 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 3,601 | $14.47 | $52106.47 |
| 2026-02-24 | JONES, JEFFREY ALAN | Chief Medical Officer | Sale | 4,582 | $14.47 | $66301.54 |
| 2026-02-24 | AHMED, NADIM | Director, President and CEO | Sale | 13,515 | $14.47 | $195562.05 |
| 2026-02-23 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 1,752 | $13.99 | $24510.48 |
| 2026-02-20 | SUMER, JACQUELYN L | Chief Legal Officer | Sale | 3,742 | $13.62 | $50966.04 |
| 2026-02-20 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 8,000 | — | — |
| 2026-02-20 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 8,000 | $14.30 | $114400.00 |
| 2026-02-20 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 3,742 | $13.62 | $50966.04 |
| 2026-02-20 | JONES, JEFFREY ALAN | Chief Medical Officer | Sale | 4,982 | $13.62 | $67854.84 |
| 2026-02-20 | FENTON, MARY KAY | Chief Financial Officer | Sale | 4,398 | $13.62 | $59900.76 |
| 2026-02-20 | AHMED, NADIM | Director, President and CEO | Sale | 16,381 | $13.62 | $223109.22 |
| 2026-02-18 | SUMER, JACQUELYN L | Chief Legal Officer | Buy | 230,000 | — | — |
| 2026-02-18 | SAVILL, CORRINE | Chief Business Officer | Buy | 175,000 | — | — |
| 2026-02-18 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 115,000 | — | — |
| 2026-02-18 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 57,500 | — | — |
| 2026-02-18 | JONES, JEFFREY ALAN | Chief Medical Officer | Buy | 300,000 | — | — |
| 2026-02-18 | FENTON, MARY KAY | Chief Financial Officer | Buy | 137,500 | — | — |
| 2026-02-18 | FENTON, MARY KAY | Chief Financial Officer | Buy | 68,750 | — | — |
| 2026-02-18 | AHMED, NADIM | Director, President and CEO | Buy | 828,000 | — | — |
| 2026-02-12 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 416 | $12.03 | $5004.48 |
| 2026-01-22 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 4,000 | $12.30 | $49200.00 |
| 2025-12-31 | FENTON, MARY KAY | Chief Financial Officer | Buy | 27 | $6.49 | $175.23 |
| 2025-12-23 | AHMED, NADIM | Director, President and CEO | Sale | 9,922 | $10.01 | $99319.22 |
| 2025-12-19 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 1,345 | $10.01 | $13463.45 |
| 2025-12-18 | SUMER, JACQUELYN L | Chief Legal Officer | Sale | 3,480 | $9.67 | $33651.60 |
| 2025-12-18 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 2,898 | $9.67 | $28023.66 |
| 2025-12-18 | JONES, JEFFREY ALAN | Chief Medical Officer | Sale | 4,632 | $9.67 | $44791.44 |
| 2025-12-15 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 995 | $11.90 | $11840.50 |
| 2025-12-12 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 2,148 | $12.38 | $26592.24 |
| 2025-11-24 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 4,000 | $12.30 | $49200.00 |
| 2025-10-28 | LYNX1, CAPITAL MANAGEMENT LP | 10% Owner | Buy | 165,667 | $8.40 | $1.39M |
| 2025-10-17 | LYNX1, CAPITAL MANAGEMENT LP | 10% Owner | Buy | 32,217 | $7.84 | $252565.17 |
| 2025-10-16 | LYNX1, CAPITAL MANAGEMENT LP | 10% Owner | Buy | 150,000 | $8.86 | $1.33M |
| 2025-10-15 | LYNX1, CAPITAL MANAGEMENT LP | 10% Owner | Buy | 51,500 | $7.94 | $409049.05 |
| 2025-10-14 | LYNX1, CAPITAL MANAGEMENT LP | 10% Owner | Buy | 15,032 | $7.59 | $114047.78 |
| 2025-10-10 | LYNX1, CAPITAL MANAGEMENT LP | 10% Owner | Buy | 277,298 | $7.36 | $2.04M |
| 2025-10-09 | LYNX1, CAPITAL MANAGEMENT LP | 10% Owner | Buy | 626,043 | $6.70 | $4.19M |
| 2025-10-08 | LYNX1, CAPITAL MANAGEMENT LP | 10% Owner | Buy | 556,300 | $6.46 | $3.59M |
| 2025-08-07 | DOYLE, MITTIE | Director | Buy | 79,456 | — | — |
| 2025-08-07 | ALLEN, ANDREW R | Director | Buy | 79,456 | — | — |
| 2025-06-12 | WEBSTER, STEPHEN W | Director | Buy | 38,513 | — | — |
| 2025-06-12 | RYAN, DAVID P. | Director | Buy | 38,513 | — | — |
| 2025-06-12 | ROSENBERG, ANTHONY | Director | Buy | 38,513 | — | — |
| 2025-06-12 | MEEK, DAVID D. | Director | Buy | 38,513 | — | — |
| 2025-06-12 | MARTIN, ANNE-MARIE | Director | Buy | 38,513 | — | — |
| 2025-02-25 | SUMER, JACQUELYN L | Chief Legal Officer | Sale | 3,756 | $8.53 | $32038.68 |
| 2025-02-25 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 3,756 | $8.53 | $32038.68 |
| 2025-02-25 | JONES, JEFFREY ALAN | Chief Medical Officer | Sale | 4,895 | $8.53 | $41754.35 |
| 2025-02-25 | AHMED, NADIM | Director, President and CEO | Sale | 12,529 | $8.53 | $106872.37 |
| 2025-02-19 | SUMER, JACQUELYN L | Chief Legal Officer | Buy | 100,000 | — | — |
| 2025-02-19 | SUMER, JACQUELYN L | Chief Legal Officer | Buy | 50,000 | — | — |
| 2025-02-19 | SAVILL, CORRINE | Chief Business Officer | Buy | 75,000 | — | — |
| 2025-02-19 | SAVILL, CORRINE | Chief Business Officer | Buy | 37,500 | — | — |
| 2025-02-19 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 100,000 | — | — |
| 2025-02-19 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 50,000 | — | — |
| 2025-02-19 | JONES, JEFFREY ALAN | Chief Medical Officer | Buy | 130,000 | — | — |
| 2025-02-19 | JONES, JEFFREY ALAN | Chief Medical Officer | Buy | 65,000 | — | — |
| 2025-02-19 | FENTON, MARY KAY | Chief Financial Officer | Buy | 120,000 | — | — |
| 2025-02-19 | FENTON, MARY KAY | Chief Financial Officer | Buy | 60,000 | — | — |
| 2025-02-19 | AHMED, NADIM | Director, President and CEO | Buy | 360,000 | — | — |
| 2025-02-19 | AHMED, NADIM | Director, President and CEO | Buy | 180,000 | — | — |
| 2025-01-06 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 4,000 | $12.51 | $50040.00 |
| 2024-12-24 | AHMED, NADIM | Director, President and CEO | Sale | 8,400 | $11.87 | $99708.00 |
| 2024-12-18 | SUMER, JACQUELYN L | Chief Legal Officer | Sale | 3,482 | $11.41 | $39729.62 |
| 2024-12-18 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 4,693 | $11.41 | $53547.13 |
| 2024-12-18 | JONES, JEFFREY ALAN | Chief Medical Officer | Sale | 4,632 | $11.41 | $52851.12 |
| 2024-12-12 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 3,489 | $12.52 | $43682.28 |
| 2024-11-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 8,000 | $15.64 | $125120.00 |
| 2024-09-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 8,000 | $18.09 | $144720.00 |
| 2024-08-08 | THISTLE, MARY | Director | Buy | 25,743 | — | — |
| 2024-07-05 | MICHAELSON, JENNIFER | Chief Scientific Officer | Sale | 8,000 | $16.33 | $130640.00 |
| 2024-07-01 | MICHAELSON, JENNIFER | Chief Scientific Officer | Buy | 2,360 | $9.00 | $21240.00 |
| 2024-06-26 | WEBSTER, STEPHEN W | Director | Buy | 15,806 | — | — |
| 2024-06-26 | RYAN, DAVID P. | Director | Buy | 15,806 | — | — |
| 2024-06-26 | ROSENBERG, ANTHONY | Director | Buy | 15,806 | — | — |
Frequently asked questions
Are CGEM insiders buying or selling?
Over the transactions on record, CGEM insiders have been net buyers, with about $2.85M in stock sold across 46 sales, against 17 open-market purchases.
Does insider selling at CGEM mean the stock will fall?
Not by itself. Most executive selling is pre-scheduled through 10b5-1 plans filed months in advance, and insiders sell for diversification, taxes, and liquidity far more often than out of any view on the price. Insider buying is the stronger signal, especially when several insiders buy around the same time, because there is usually only one reason to put personal cash into the stock.
Which CGEM insiders are selling the most?
Recent selling is concentrated in a few names. MICHAELSON, JENNIFER accounts for the largest share on record, with about $1.59M sold. Selling by one or two individuals matters less than broad selling across the whole leadership team, which is the pattern worth watching.